

## State of Oklahoma SoonerCare

## Orserdu™ (Elacestrant) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Pharmacy Billing (NDC:	) Start Date (or	date of next dose):
Dose:	Regimen:	
Billing Provider Information		
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	·
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
<b>Criteria</b>		
Additional Information:  A disease estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative? Yes No B. Is tumor positive for ESR1-mutation? Yes No C. If female, is member postmenopausal? Yes No D. Has disease progressed after at least 1 prior endocrine therapy? Yes No If diagnosis is not listed above, please indicate diagnosis:  Additional Information:		
<ol> <li>Does member have any evidence of progressive disease while on elacestrant? Yes No</li> <li>Has the member experienced adverse drug reactions related to elacestrant therapy? Yes No</li> <li>If yes, please specify adverse reactions:</li> </ol>		
Additional Information:		
Prescriber Signature:  I certify that the indicated treatment the best of mv knowledge. Failure to		Date:and all information is true and correct to

## PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 241 4/28/2023